Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper presents an interactive quiz related to a study by Deng et al. (2022) in the Journal of Investigative Dermatology, examining androgen receptor-mediated paracrine signaling in androgenetic alopecia, but it provides no new clinical findings.

This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.

Female and male AGA are different diseases.

This study found that aminoguanidine induced increased VEGF mRNA expression in stored hair follicle micrografts, suggesting potential for developing growth-promoting storage solutions in hair restoration surgery.

This study found that androgenetic alopecia is the leading cause of hair loss in adolescents and may indicate endocrine disorders, emphasizing the need for accurate diagnosis.

This article provides a critical overview of recent discoveries in the genetics and molecular processes involved in androgenetic alopecia, focusing on its polygenic basis and DHT dependency, but reports no new clinical results.

This review explores the link between androgenetic alopecia, advanced glycation end products, and RAGE, noting their potential role in exacerbating oxidative stress and inflammation related to hair follicle miniaturization.

This study highlights the importance of clinicians understanding the effects of gender-affirming hormones like testosterone, estrogen, and antiandrogens on hair growth, to effectively diagnose and treat androgenetic alopecia in gender minority patients.

This study systematically reviewed androgenetic alopecia's clinical features, mechanisms, and treatments, highlighting that current drugs have limitations but emerging therapies and personalized treatment strategies could enhance efficacy and outcomes.

This case report describes the first known instance of hair loss linked to agomelatine, which resolved after the drug was discontinued.

In this randomized controlled trial, the topical application of a PGA solution significantly increased hair density in patients with androgenetic alopecia compared to placebo, with no adverse reactions reported over 24 weeks, suggesting its potential as a safe and effective treatment option.

In a study on wound healing, researchers described injectable POEGMA‐DA hydrogels as a promising non-toxic alternative to traditional wound closure methods, showing effective tissue adhesion and enhanced regeneration of skin structures in a mouse model without significant inflammation.

This review discusses potential links between early-onset androgenetic alopecia and exposure to endocrine disruptors in adolescents, but reports no clinical results; the authors suggest further investigation.

Hair loss treated with minoxidil, finasteride, laser/light, hair transplant, and scalp prostheses; more research needed for skin of color.

This study found that topical adenosine significantly increased the ratio of thick hairs and contributed to global improvement in Japanese men with androgenetic alopecia compared to niacinamide, with no observed adverse events.

This review outlines that minoxidil (topical and oral) and 5α-reductase inhibitors are the most effective treatments for androgenetic alopecia, with additional therapies like platelet-rich plasma and hair transplantation enhancing results, emphasizing the need for individualized, combination approaches.

This study examines the pathogenetic mechanisms and morphological changes in androgenetic alopecia, highlighting the role of genetic and hormonal factors like dihydrotestosterone in hair follicle changes, which is crucial for developing effective diagnostics and treatments.

This study tested a novel cryo-carboxy dispensing device for treating androgenetic alopecia in six volunteers and found an unexpectedly rapid and positive response, with significant hair regrowth observed by day 90, prompting early conclusion of the trial.

This study found a statistically significant association between androgenetic alopecia and coronary artery disease in men, with higher grades of alopecia, especially involving the vertex, indicating a greater risk.

This study found that increased levels of PGD2 and prostacyclin and decreased levels of PGE2 and PGF2α were associated with baldness in androgenetic alopecia, suggesting potential targets for treatment.

This study found that combining microneedling with a topical glycosaminoglycan lotion improved hair density and follicular thickness in patients with androgenetic alopecia, with no adverse effects except mild pain, suggesting potential synergistic benefits as a treatment.

This review discusses the pathological factors and comorbidities associated with androgenetic alopecia and reports no new clinical results, emphasizing the need for improved understanding and treatment in clinical practice.

In this study, activated PRP injections appeared to promote hair growth in AGA-affected scalp skin transplanted onto mice, compared to non-activated PRP.

This study found that the dietary supplement RJ-SP4AGA significantly improved hair growth and reduced hair loss in post-menopausal women with androgenetic alopecia over 16 weeks.

This study found that androgenetic alopecia treatments, especially dutasteride, are associated with a small increased risk of adverse events like sexual dysfunction and dermatologic reactions.

This abstract discusses the prevalence and typical onset of androgenetic alopecia but reports no clinical findings.

This study suggests that elevated aldosterone may contribute to androgenic alopecia development and its association with higher hypertension prevalence, emphasizing the importance of blood pressure screening in affected patients.

This article previews a Journal of Investigative Dermatology quiz on diagnosing male androgenetic alopecia and offers no new research results.

Prostaglandin D2, found in higher levels in bald scalps, stops hair growth and could be a target for treating hair loss.

This guideline summarizes evidence-based and expert-based recommendations for treating androgenetic alopecia, adapted by an Italian expert group in alignment with Italian pharmacological policies.